Enliven Therapeutics Inc (ELVN) Stock Price, Quote & News

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 647 8519

Website: www.enliventherapeutics.com

Address:

6200 Lookout Road, Boulder, United States

mhoward1711 May. 13 at 9:20 PM

$ELVN interesting pm movement here

1 · Reply

thedentite May. 13 at 3:32 PM

$ELVN Where is everyone? Bob, you out there? I'm happy I bought on margin yesterday.

1 · Reply

thedentite May. 13 at 2:32 PM

$ELVN

0 · Reply

mikesterz7 May. 12 at 9:47 PM

$ELVN Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm.

0 · Reply

thedentite May. 12 at 7:17 PM

$ELVN 80 bucks, I'll take that.

0 · Reply

Quantumup May. 12 at 7:08 PM

Guggenheim y'day🏁 $ELVN Buy; $80—its PT is supported by conservative assumptions for ELVN-001 (75% PoS in 2L CML, 50% peak shr, 25% PoS in 1L CML, 20% peak shr)= $2.9B risk-adj'd US peak sales in 2043—up to $5B peak. TERN - $MRK $NVS Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2054276939058176483?s=20

0 · Reply

StocktwitsNews May. 12 at 6:46 PM

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil $ELVN $VTI $IWM https://stocktwits.com/news/equity/markets/elvn-stock-climbs-as-guggenheim-launches-coverage-with-80-dollar-price-target-conference-data-unveil/cZXXmu1Reiw

0 · Reply

thedentite May. 12 at 2:20 PM

$ELVN OH HELL YEAH! Now we are having fun.

0 · Reply

Merlintrader May. 9 at 12:37 PM

$PTCT 3 Biotech Stocks to Watch: PTC Therapeutics Enliven Therapeutics ($ELVN) and Edgewise Therapeutics ($EWTX) https://www.merlintrader.com/biotech-stocks-to-watch-may09-2026/

0 · Reply

BobBobbertonnn May. 7 at 5:48 PM

$ELVN ah yes, ai and energy bubble popping so lets go down below $40 on an ideosyncratic small / mid cap biotech play hahaha. how are there still sellers at this price. They ran TERN to $5B over misleading data but $2.5B is pricey? smh deleting stock app until earnings 😂

0 · Reply

Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress

May 12, 2026, 9:53 AM EDT - 1 day ago

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

2026-05-12T08:45:09.000Z - 1 day ago

Guggenheim starts Enliven with Buy on leukemia opportunity

2026-05-12T00:30:09.000Z - 1 day ago

Enliven initiated with a Buy at Guggenheim

2026-05-08T18:30:31.000Z - 5 days ago

Enliven price target raised to $59 from $41 at Goldman Sachs

May 7, 2026, 4:05 PM EDT - 6 days ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

2026-04-30T19:32:47.000Z - 13 days ago

Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho

MRK TERN

2026-04-27T09:20:09.000Z - 16 days ago

Enliven price target raised to $55 from $36 at Clear Street

2026-03-26T16:07:38.000Z - 6 weeks ago

Enliven rises 11.0%

2026-03-26T10:21:09.000Z - 6 weeks ago

Enliven price target raised to $56 from $48 at H.C. Wainwright

2026-03-25T11:50:36.000Z - 7 weeks ago

Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck

MRK TERN

2026-03-25T11:07:51.000Z - 7 weeks ago

Enliven price target raised to $45 from $41 at Mizuho

Mar 3, 2026, 10:30 AM EST - 2 months ago

Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 2 months ago

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

2026-01-08T14:06:37.000Z - 4 months ago

Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML

Jan 8, 2026, 9:00 AM EST - 4 months ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 7, 2026, 9:00 AM EST - 4 months ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Dec 11, 2025, 4:21 PM EST - 5 months ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

2025-12-11T14:10:43.000Z - 5 months ago

Enliven announces the appointment of Fair as CEO

Dec 11, 2025, 9:00 AM EST - 5 months ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Nov 18, 2025, 11:00 AM EST - 6 months ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Aug 25, 2025, 6:20 PM EDT - 9 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Jun 16, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 13, 2025, 1:30 PM EDT - 11 months ago

Enliven Therapeutics Transcript: Study Update

Jun 13, 2025, 9:30 AM EDT - 11 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 11 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:02 AM EDT - 11 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 1:00 PM EDT - 1 year ago

Enliven Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 22, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 9:56 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Apr 2, 2025, 4:03 PM EDT - 1 year ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 4, 2025, 10:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Nov 19, 2024, 4:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Jun 10, 2024, 3:20 PM EDT - 2 years ago

Enliven Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Study Update

Apr 11, 2024, 7:55 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Oct 13, 2022, 5:00 PM EDT - 3 years ago

Enliven Therapeutics Transcript: M&A Announcement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 5, 2022, 7:00 AM EST - 4 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Dec 14, 2021, 7:00 AM EST - 4 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Nov 22, 2021, 7:00 AM EST - 4 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 16, 2021, 7:00 AM EST - 4 years ago

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Nov 9, 2021, 7:00 AM EST - 4 years ago

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Nov 4, 2021, 4:01 PM EDT - 4 years ago

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Nov 4, 2021, 9:17 AM EDT - 4 years ago

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

mhoward1711 May. 13 at 9:20 PM

$ELVN interesting pm movement here

1 · Reply

thedentite May. 13 at 3:32 PM

$ELVN Where is everyone? Bob, you out there? I'm happy I bought on margin yesterday.

1 · Reply

thedentite May. 13 at 2:32 PM

$ELVN

0 · Reply

mikesterz7 May. 12 at 9:47 PM

$ELVN Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm.

0 · Reply

thedentite May. 12 at 7:17 PM

$ELVN 80 bucks, I'll take that.

0 · Reply

Quantumup May. 12 at 7:08 PM

0 · Reply

StocktwitsNews May. 12 at 6:46 PM

0 · Reply

thedentite May. 12 at 2:20 PM

$ELVN OH HELL YEAH! Now we are having fun.

0 · Reply

Merlintrader May. 9 at 12:37 PM

$PTCT 3 Biotech Stocks to Watch: PTC Therapeutics Enliven Therapeutics ($ELVN) and Edgewise Therapeutics ($EWTX) https://www.merlintrader.com/biotech-stocks-to-watch-may09-2026/

0 · Reply

BobBobbertonnn May. 7 at 5:48 PM

0 · Reply

BobBobbertonnn May. 5 at 3:54 PM

$ELVN Sigh*** just been a $40 magnet for couple weeks now. Offering @$40? They have cash? Volume low? Waiting for news in next couple of weeks? Odd price action. Lets hope for accumulation ~$40 then maybe the MM will let us go onward and upward

1 · Reply

thedentite May. 5 at 1:39 PM

$ELVN Yes! It's about time. Now on to 50.

1 · Reply

BillionerOfKing May. 1 at 6:08 PM

$ELVN Current Stock Price: $42.03 Contracts to trade: $40.0 ELVN May 15 2026 Call Entry: $1.90 Exit: $3.73 ROI: 96% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BobBobbertonnn May. 1 at 2:30 PM

$ELVN 🤔

0 · Reply

BobBobbertonnn Apr. 30 at 4:51 PM

$ELVN will we ever go green again? asking for a friend lolol. Every time i glance bids 5-10x the ask but we keep dipping smh hahah

1 · Reply

BobBobbertonnn Apr. 28 at 9:53 PM

$ELVN roller coaster AF haha. Someone sniped shares for $32 then back up to $43.84 hahah what in thr world

0 · Reply

thedentite Apr. 28 at 2:06 PM

$ELVN Looks like a repeat of March 11-18. We could see another leap up within the next few days.

1 · Reply

STACKD0E Apr. 22 at 1:29 AM

$ELVN Next stop$65 🙃✨️

2 · Reply

thedentite Apr. 21 at 2:39 PM

$ELVN Leg up to 50 is coming.

0 · Reply

blue81 Apr. 18 at 10:58 AM

$ELVN mm know dmr will be 40 percent and up. , next month we will. See where data will Fall 🍁🍁🍁🍁

0 · Reply

Whiskeyunderthebed Apr. 17 at 8:04 PM

$ELVN crazy stuff!

0 · Reply

thedentite Apr. 17 at 5:13 PM

$ELVN This is getting kind of crazy. I tried to tell my $ALT buddies a while ago but they weren’t interested. I will say that board has way better posts though…

1 · Reply

Market Cap	2.41B
Revenue (ttm)	0.00
Net Income (ttm)	-103.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,212,500
Avg Vol	1,187,850
Day's Range	N/A - N/A
Shares Out	60.90M
Stochastic %K	70%
Beta	0.32
Analysts	Strong Sell
Price Target	$53.88